NASDAQ: BGNEBeigene Ltd Stock Ownership - Who owns Beigene?
Insider buying vs selling
Have Beigene Ltd insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| John Oyler | Chief Executive Officer | 2024-04-11 | 5,008 | $146.09 | $731.61kSell |
| John Oyler | Chief Executive Officer | 2024-04-11 | 2,811 | $147.74 | $415.31kSell |
| John Oyler | Chief Executive Officer | 2024-04-11 | 4,265 | $146.82 | $626.17kSell |
| John Oyler | Chief Executive Officer | 2024-04-10 | 60 | $150.85 | $9.05kSell |
| John Oyler | Chief Executive Officer | 2024-04-10 | 11,514 | $148.40 | $1.71MSell |
| John Oyler | Chief Executive Officer | 2024-04-10 | 12,501 | $149.15 | $1.86MSell |
| John Oyler | Chief Executive Officer | 2024-04-10 | 2,641 | $149.79 | $395.60kSell |
| John Oyler | Chief Executive Officer | 2024-04-09 | 7,924 | $154.21 | $1.22MSell |
| John Oyler | Chief Executive Officer | 2024-04-09 | 2,734 | $153.47 | $419.59kSell |
| John Oyler | Chief Executive Officer | 2024-04-09 | 542 | $152.28 | $82.54kSell |
BGNE insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when BGNE insiders and whales buy or sell their stock.
BGNE Shareholders
What type of owners hold Beigene Ltd stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Hillhouse Capital Advisors Ltd | 10.82% | 147,035,258 | $21.19B | Insider |
| Hhlr Advisors Ltd | 10.51% | 142,888,241 | $20.59B | Insider |
| Hillhouse Capital Management Ltd | 8.15% | 110,866,146 | $15.98B | Insider |
| Cb Biotech Investment Ltd | 1.44% | 19,601,138 | $2.82B | Insider |
| Amgen Inc | 1.39% | 18,943,802 | $2.73B | Insider |
| Baker Bros Advisors LP | 0.78% | 10,568,897 | $1.52B | Institution |
| Baker Bros Advisors LP | 0.71% | 9,701,712 | $1.40B | Insider |
| Merck Co Inc | 0.58% | 7,942,314 | $1.14B | Insider |
| Capital International Investors | 0.47% | 6,336,872 | $913.27M | Institution |
| Xiaodong Wang | 0.42% | 5,683,860 | $819.16M | Insider |
BGNE vs Biotech Stocks
Beigene Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.